(Q51625833)

English

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

scientific article published on 9 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

N Putzki

1

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

O Yaldizli

2

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

M Mäurer

3

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

S Cursiefen

4

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

S Kuckert

5

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

C Klawe

6

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

M Maschke

7

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

B Tettenborn

8

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

V Limmroth

9

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

publication date

9 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

17

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

1

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

31-37

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Non-specific immunosuppressants in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02728.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2009.02728.X

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/19614963

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51625833&oldid=1232005083"